



# A Guide to Your Treatment with **ENHERTU**

This booklet has been provided as a service to medicine by AstraZeneca for patients who have been prescribed Enhertu (trastuzumab deruxtecan)

Trastuzumab Deruxetecan 'Enhertu' medicine is not approved across all GCC countries, Please refer to local prescribing information in registered markets for further information

# This brochure may help you get to know your treatment

**Now that you have been prescribed ENHERTU,  
you might have some questions.**

Read this carefully before you start treatment with ENHERTU and each time you get an infusion. This leaflet is a summary and will not tell you everything about this drug.

Talk to your healthcare professional about your medical condition and treatment and ask if there is any new information about ENHERTU.



## Table of contents

<b>Get to know ENHERTU</b> .....	<b>4</b>
What is ENHERTU used for?	
How does ENHERTU work?	
What are the ingredients in ENHERTU?	
<b>Important information about ENHERTU</b> .....	<b>5</b>
How to take ENHERTU	
Usual dose	
Missed dose	
<b>Warnings and precautions when it comes to ENHERTU</b>	
Serious warnings and precautions with ENHERTU treatment.....	<b>6</b>
Possible side effects from using ENHERTU.....	<b>8</b>
Other warnings you should know about.....	<b>9</b>
Additional safety information .....	<b>10</b>

# Get to know ENHERTU

## What is ENHERTU used for?<sup>1,2</sup>

ENHERTU is used in adults who have:

- HER2-positive breast cancer that has spread to other parts of the body (metastatic) or cannot be taken out by surgery **and**
- also received a prior treatment that targeted HER2-positive breast cancer

## How does ENHERTU work?<sup>1,2</sup>

ENHERTU contains the active substance trastuzumab deruxtecan, which is made up of a monoclonal antibody connected to a medicine intended to kill cancer cells.

The monoclonal antibody delivers the medicine to cancer cells that express HER2 proteins (known as HER2 positive).

Once ENHERTU enters the cell, the medicine becomes active and kills the cancer cells.

## What are the ingredients in ENHERTU?<sup>1,2</sup>

**Medicinal ingredients:** trastuzumab deruxtecan

**Non-medicinal ingredients:** L histidine, L histidine hydrochloride monohydrate, polysorbate 80, sucrose.

# Important information about ENHERTU



## How to take ENHERTU<sup>1</sup>

ENHERTU will be given to you by a healthcare professional.



## Usual dose<sup>1,2</sup>

ENHERTU will be given to you in a hospital or clinic.

- The recommended dose of ENHERTU is 5.4 mg for every kilogram of your body weight, every 3 weeks.
- Your doctor or nurse will give you ENHERTU through an infusion into your vein (IV).
- Your first infusion will be given to you over 90 minutes. If you have no problems with the first infusion, the infusion on your next visits may be given over 30 minutes.
- Your doctor will decide how many treatments you need.
- Before each ENHERTU infusion, your doctor may give you medicines to help prevent nausea and vomiting.
- If you experience infusion-related symptoms, your doctor or nurse may slow, interrupt, or stop your treatment.



## Missed dose<sup>1,2</sup>

If you miss an appointment to get ENHERTU:

- Call your doctor right away to reschedule your appointment.
- It is very important that you do not miss a dose of this medicine.

Do not stop treatment with ENHERTU unless you have discussed this with your doctor. If you have any further questions about your treatment, ask your doctor.



# Precautions when it comes to ENHERTU

## Serious warnings and precautions with ENHERTU treatment



Lung problems that may be severe, life-threatening or that may lead to death. Tell your healthcare provider right away if you get any of the following signs and symptoms at any time during treatment:<sup>1,2</sup>

- cough
- trouble breathing or shortness of breath
- fever
- other new or worsening breathing symptoms

If you develop lung problems your healthcare provider may treat you with corticosteroid medicines.<sup>1</sup>



Harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ENHERTU.<sup>1,2</sup>

- If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ENHERTU.
- Females who are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for at least 7 months after the last dose.
- Males who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for at least 4 months after the last dose.



There is a risk of ENHERTU medication errors. Verify with your healthcare provider that you are receiving the authorized ENHERTU (trastuzumab deruxtecan) dose and NOT trastuzumab or trastuzumab emtansine.<sup>1,2</sup>

## Do not use ENHERTU if:<sup>1,2</sup>

You are allergic to trastuzumab deruxtecan or to any ingredients in ENHERTU. If you are not sure, talk to your healthcare professional before you are given ENHERTU.

## To help avoid side effects and ensure proper use, talk to your healthcare professional before you take ENHERTU. Talk about any health conditions or problems you may have, including if you:<sup>1,2</sup>

- have or have had any lung problems, any heart problems, or any blood problems (low blood count).



## What are possible side effects from using ENHERTU?

Like all medicines, this medicine can cause side effects, although not everybody gets them. Tell your doctor if you experience any side effects, including those not listed in this booklet.<sup>1,2</sup>

While you are taking ENHERTU:<sup>1,2</sup>

- Your doctor will carry out tests before and during your treatment with ENHERTU.
- Depending on the side effects you experience, your doctor may decide to lower your dose, temporarily stop your treatment, or permanently stop your treatment.

**When you first receive this medicine and anytime during treatment, tell your doctor or nurse right away if you notice any of the following symptoms, because some of them may be signs of a serious or possibly fatal condition.**

Getting medical treatment right away may help keep these problems from becoming more serious.<sup>1,2</sup>



- Cough, shortness of breath, fever, or other new or worsening breathing problems.
- These may be symptoms of a serious and potentially fatal lung disease (interstitial lung disease [ILD]/pneumonitis).



- Chills, fever, sores in your mouth, stomach pain or pain when urinating.
- These may be symptoms of an infection caused by low levels of a type of white blood cell called neutrophils (neutropenia).



- New or worsening shortness of breath, cough, fatigue, swelling of your ankles or legs, irregular heartbeat, sudden weight gain, dizziness, or loss of consciousness.
- These may be symptoms of a problem with your heart's ability to pump blood (decreased left ventricular ejection fraction [LVEF]).



- Reactions related to the infusion: Chills or shaking, shortness of breath or wheezing, itching, rash or hives, flushing, dizziness, fever, feeling like passing out.

## Other warnings you should know about



### Children and adolescents<sup>1</sup>

- ENHERTU is not recommended for anyone under the age of 18 years.



### Pregnancy<sup>1,2</sup>

- ENHERTU is not recommended if you are pregnant because this medicine may cause harm to the unborn baby.
- Tell your doctor before using ENHERTU if you are pregnant, think you may be pregnant or are planning to have a baby.
- Use effective contraception to avoid becoming pregnant while you are being treated with ENHERTU. Talk to your doctor about the best contraception for you.
- Females should continue to take contraception for at least 7 months after your last dose of ENHERTU. Talk to your doctor before stopping your contraception.
- Male patients with a female partner who could become pregnant should use effective contraception during treatment and for at least 4 months after the last dose of ENHERTU.
- If you do become pregnant during treatment with ENHERTU, tell your doctor right away.



### Breastfeeding<sup>1,2</sup>

- You should not breastfeed during treatment with ENHERTU.
- You should not breastfeed for at least 7 months after your last treatment of ENHERTU.
- It is not known whether the ingredients in ENHERTU pass into breast milk. Talk to your doctor about this.

### Fertility<sup>1,2</sup>

- Talk to your doctor about sperm storage before treatment with ENHERTU because the medicine may reduce your fertility. Do not freeze or donate sperm throughout the treatment period, and for at least 4 months after the final dose of ENHERTU.



### Driving and using machines<sup>1,2</sup>

ENHERTU may reduce your ability to drive or use machines.

Be careful if you feel tired, dizzy, or have a headache.

**Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements, or alternative medicines.**



## Additional safety information

- Talk to your healthcare professional.





Not all possible side effects are listed on this card.

Please read the Enhertu® (Trastuzumab deruxtecan) Patient Information Leaflet or talk with your doctor for more information about side effects.

For further information reach out to AstraZeneca Medical Information on:

Email: [mediinfo-ksa@astrazeneca.com](mailto:mediinfo-ksa@astrazeneca.com)

Phone: +966 11 2249235

Portal: <https://contactazmedical.astrazeneca.com>

If you experience any side effects, talk to your health care provider. This includes any possible side effects not listed in the Package Leaflet.

You can also report side effects to AstraZeneca patient Safety:

Email: [ksa.ae@astrazeneca.com](mailto:ksa.ae@astrazeneca.com)

Phone : +966 11 2249235

Portal: <https://contactazmedical.astrazeneca.com>

Or SFDA reporting information:

Email: [npc.drug@sfd.gov.sa](mailto:npc.drug@sfd.gov.sa)

Toll free phone: 19999

Portal: <https://ade.sfd.gov.sa>

#### GULF

**For Reporting Adverse events and/or Product Quality Complaints:**

Website: <https://contactazmedical.astrazeneca.com>

E-mail: [Patientsafety-azgulf@astrazeneca.com](mailto:Patientsafety-azgulf@astrazeneca.com)

Call AstraZeneca FZ LLC land line: +971 43624888.

**For Medical information Enquires:**

Website: <https://contactazmedical.astrazeneca.com>

E-mail: [gulf-medicalinfo@astrazeneca.com](mailto:gulf-medicalinfo@astrazeneca.com)

Call AstraZeneca FZ LLC land line: +971 43624888

#### SAUDI

For Medical information please send an email to [medinfoksa@astrazeneca.com](mailto:medinfoksa@astrazeneca.com)

For AE reporting send email to [ksa.ae@astrazeneca.com](mailto:ksa.ae@astrazeneca.com)



#### GULF

AstraZeneca FZ LLC Gulf P.O. Box: 505070 Dubai, UAE;

Dubai Healthcare City, Building 27, Block D 2nd Floor;

Tel: +971 (4) 362 4888; Fax: +971 (4) 362 4898/9

#### SAUDI

Al-Nakhla Tower - Floor 13th Ath Thumamah, Road - Al Sahafa

District. 7198 Unit No. 20 Riyadh 13315 – 3642.

Tel: +966 (011) 22 492 00; Fax: +966 (011) 22 492 91

Date of Preparation: January 2023; Date of Expiry: January 2025

Approval code: **15-6501**